DS-2325 / Daiichi Sankyo - LARVOL DELTA

A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome (clinicaltrials.gov) - P1/2 | N=9 | Terminated | Sponsor: Daiichi Sankyo | Active, not recruiting ➔ Terminated; The study was terminated based on a business decision by the Sponsor.

Trial termination

A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome (clinicaltrials.gov) - P1/2 | N=9 | Active, not recruiting | Sponsor: Daiichi Sankyo | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome (clinicaltrials.gov) - P1/2 | N=12 | Recruiting | Sponsor: Daiichi Sankyo | Trial primary completion date: Jun 2024 ➔ Nov 2024

Trial primary completion date

Single- and multiple-ascending dose studies of DS-2325a, a KLK5 inhibitor for the treatment of Netherton syndrome (SID 2024) - No abstract available

KLK5

A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome (clinicaltrials.gov) - P1/2 | N=12 | Recruiting | Sponsor: Daiichi Sankyo, Inc. | Phase classification: P1b/2 ➔ P1/2

Phase classification

A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome (clinicaltrials.gov) - P1/2 | N=12 | Recruiting | Sponsor: Daiichi Sankyo, Inc.

New P1/2 trial

A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome (clinicaltrials.gov) - P1b/2 | N=12 | Recruiting | Sponsor: Daiichi Sankyo, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Daiichi Sankyo, Inc. | Recruiting ➔ Completed

Trial completion

A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects (clinicaltrials.gov) - P1 | N=64 | Completed | Sponsor: Daiichi Sankyo, Inc. | Recruiting ➔ Completed

Trial completion

A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Daiichi Sankyo, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Daiichi Sankyo, Inc.

New P1 trial

A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: Daiichi Sankyo, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects (clinicaltrials.gov) - P1 | N=64 | Not yet recruiting | Sponsor: Daiichi Sankyo, Inc.

New P1 trial